Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2013-000052-17-GB
EUCTR2013-000052-17-GB
Active, not recruiting
Not Applicable

Pilot study to investigate the early prediction of toxicity following induction chemotherapy in Ewing’s sarcoma by blood-borne biomarkers and correlation with age-dependent pharmacokinetic variation - Pharmacokinetic variation and toxicity in Ewing's sarcoma

The Newcastle Upon Tyne Hospitals NHS Foundation Trust0 sitesAugust 6, 2013
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsEwing sarcoma patientsMedDRA version: 17.0Level: PTClassification code 10015560Term: Ewing's sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
DrugsCyclophosphamideEposinDoxorubicin HydrochlorideVincristine SulphateIfosfamide

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Ewing sarcoma patients
Sponsor
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
Status
Active, not recruiting
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 6, 2013
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •a) Diagnosis of histologically confirmed Ewing sarcoma.
  • •b) Receiving VIDE or VDC/IE as part of standard clinical treatment.
  • •c) Single or double lumen central venous catheter in place.
  • •d) Written informed consent.
  • •e) Protocol approval by national and local ethics committee, regulatory authority and Trust R\&D Departments.
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range: 90
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 30
  • •F.1\.3 Elderly (\>\=65 years) no

Exclusion Criteria

  • •a) Receiving non\-standard dose chemotherapy.
  • •b) Glomerular filtration rate \<60 ml/min/1\.73m2\.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Pharmacokinetic variation and toxicity in Ewing's sarcomaEwing's sarcomaCancer
ISRCTN52616678The Newcastle Upon Tyne Hospitals NHS Foundation Trust (UK)139
Not yet recruiting
Not Applicable
The effect of graduated return to high-intensity exercise on time to return to play in the context of sports-related concussions.Sports-related concussionMild Traumatic Brain Injury
ACTRN12618000485235Dr Hamish Osborne50
Completed
Phase 1
CytoMegaloVirus: Alternate donor Study of Pre-Emptive Cellular Therapy
ISRCTN75391842Cell Medica Ltd (UK)18
Active, not recruiting
Phase 1
A prospective phase I/II study to investigate the feasibility, safety and efficacy of IL-15 activated cytokine induced killer (CIK) cells in relapsing patients with acute leukemia or myelodysplastic syndromes after allogeneic stem cell transplantatiorelapsing acute leukemia, relapsing myelodysplastic syndromesMedDRA version: 17.0Level: LLTClassification code 10000835Term: Acute leukemiaSystem Organ Class: 100000004864MedDRA version: 17.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2013-005446-11-DEGoethe-University Frankfurt40
Recruiting
Not Applicable
A randomized pilot study to search the predictive parameters of PSK responder in patients with colorectal cancercolorectal cancer
JPRN-UMIN000010046Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine210